This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Aviragen Therapeutics, Inc.
Drug Names(s): LANI, CS8958, CS-8958, Inavir (Japan)
Description: CS-8958 is a long-acting neuraminidase inhibitor (LANI) that is expected to be used as single administration for treatment and once a week for prophylaxis. Non-clinical studies have confirmed its effectiveness against the H5N1 avian influenza virus in addition to its effectiveness against both A and B type seasonal influenza viruses.
Biota and Daiichi Sankyo
In October 2003, Biota and Sankyo entered a collaboration and licence agreement for the development of influenza compounds. Under the agreement Biota and Sankyo will pool their drugs into a single pipeline of novel products, which will be offered to prospective licensing partners for further development and marketing. All licensing revenue, milestone payments and royalties from the partnership will be shared equally between Biota and Sankyo.
In March 2009, Daiichi Sankyo signed a contract to manufacture and market the product in Japan, pending the successful completion of the pivotal Phase III clinical studies and on obtaining registration approval. Biota, as one of the owners, will receive an undisclosed royalty on sales and a number of fixed sum payments on the achievement of certain sales milestones in the Japanese market.
Biota and AMRI
In April 2012, AMRI was selected by Biota Holdings to further develop and manufacture the...See full deal structure in Biomedtracker
Partners: Daiichi Sankyo Co., Ltd. Albany Molecular Research, Inc. HealthCare Royalty Partners
Additional information available to subscribers only: